Morningstar

Actinium Pharmaceuticals Inc ATNM

Morningstar Rating
Unlock
Stock XASE Rating as of
$1.79 −0.01 (0.56%)
View Full Chart
As of Delayed Price Closed

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
ATNM is trading at a 781% premium.
Price
$1.78
Fair Value
$3.89
Uncertainty
Extreme
1-Star Price
$821.28
5-Star Price
$3.26
Economic Moat
Gqb
Capital Allocation
—

News

View All

Trading Information

Previous Close Price
$1.80
Day Range
$1.78–1.84
52-Week Range
$1.33–10.24
Bid/Ask
$1.77 / $1.81
Market Cap
$55.77 Mil
Volume/Avg
275,543 / 815,882

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
621.53
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
49
Website
https://www.actiniumpharma.com

Comparables

Valuation

View More
Metric
ATNM
PSTX
ACRV
Price/Earnings (Normalized)
 ———
Price/Book Value
 1.254.741.04
Price/Sales
 621.533.20—
Price/Cash Flow
 ———
Price/Earnings
No chart available

Financial Strength

Metric
ATNM
PSTX
ACRV
Quick Ratio
 8.842.4416.00
Current Ratio
 8.952.4816.16
Interest Coverage
 —−11.50—
Quick Ratio
ATNM
PSTX
ACRV

Profitability

Metric
ATNM
PSTX
ACRV
Return on Assets (Normalized)
 −42.47%−33.29%−34.86%
Return on Equity (Normalized)
 −86.13%−92.95%−38.09%
Return on Invested Capital (Normalized)
 −91.06%−46.70%−36.96%
Return on Assets
ATNM
PSTX
ACRV

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
ZknpwvtdvkWmwml$554.5 Bil
 Vertex Pharmaceuticals Inc
VRTX
WlcpvqfybJzkrp$119.5 Bil
 Regeneron Pharmaceuticals Inc
REGN
YrfrqtnTswqhjz$114.6 Bil
 Alnylam Pharmaceuticals Inc
ALNY
RbjjtnxqYxjtt$35.2 Bil
 argenx SE ADR
ARGX
ShlnxvwklMgdv$31.7 Bil
 BioNTech SE ADR
BNTX
WzzxlvkDmrd$28.0 Bil
 Moderna Inc
MRNA
KrdpyqxjYjsgr$24.6 Bil
 United Therapeutics Corp
UTHR
DjsnzxsykXkmb$15.9 Bil
 Biomarin Pharmaceutical Inc
BMRN
QcckpqmfTqmlxmt$13.4 Bil
 Royalty Pharma PLC Class A
RPRX
HkygkstrWglps$12.6 Bil

Sponsor Center